Key takeaways
- • Frequency: Uncommon — ~3-10%, usually mild and self-limited.
- • Trial reference: STEP-1 / SURMOUNT-1 pooled adverse events (3-10%).
- • Management: Rotate sites with each dose — alternate among abdomen (2+ inches from the navel), upper outer thigh, and back of the upper arm
- • Call your prescriber if: Spreading redness, warmth, or pus (possible infection)
Why this happens
A local irritation or mild immune response to the injection. Reusing the same spot, injecting cold medication straight from the fridge, injecting into muscle instead of fat, or imperfect technique all increase the chance of a reaction.
How to manage it
- Rotate sites with each dose — alternate among abdomen (2+ inches from the navel), upper outer thigh, and back of the upper arm
- Let the pen reach room temperature (~30 minutes out of the fridge) before injecting
- Inject into subcutaneous fat, not muscle, and don’t rub the site afterward
- Clean the skin and let it dry before injecting
- A cool compress can ease itching or a small lump
- Never reuse needles or pens past their labeled use
GLP1Zoom doesn't prescribe — these are general management guidance from FDA labels and clinical trial reports. Personalized recommendations require your prescribing clinician.
When to call your doctor
Red flags — seek medical attention
- • Spreading redness, warmth, or pus (possible infection)
- • Hives, facial/throat swelling, or trouble breathing (severe allergic reaction — call 911)
- • A reaction that worsens or persists beyond about a week
- • A hard lump that keeps growing or becomes painful
Drug-specific notes
- All injectable GLP-1s: Applies to Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, etc.; rates are low and reactions usually mild
- Rybelsus: Oral tablet — no injection-site reactions; GI effects apply instead
Frequently asked questions
Why does injection-site reactions happen on GLP-1 medications?
A local irritation or mild immune response to the injection. Reusing the same spot, injecting cold medication straight from the fridge, injecting into muscle instead of fat, or imperfect technique all increase the chance of a reaction.
When should I call a doctor about injection-site reactions?
Spreading redness, warmth, or pus (possible infection) Hives, facial/throat swelling, or trouble breathing (severe allergic reaction — call 911) A reaction that worsens or persists beyond about a week A hard lump that keeps growing or becomes painful
How common is injection-site reactions on GLP-1 medications?
Uncommon — ~3-10%, usually mild and self-limited
Other GLP-1 symptoms
Gastrointestinal
Nausea on GLP-1 medications
Gastrointestinal
Diarrhea on GLP-1 medications
Gastrointestinal
Constipation on GLP-1 medications
Systemic
Fatigue on GLP-1 medications
Neurological
Headache on GLP-1 medications
Skin / Hair
Hair loss on GLP-1 medications
Symptom management is general guidance based on FDA-approved prescribing information. Always discuss specifics with your prescribing clinician. In medical emergencies, call 911 or go to the nearest emergency department. Full disclaimer.
References
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly for Treatment of Obesity (Jastreboff et al., NEJM)(2022)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms and Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide in Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes in T2D (Marso et al., NEJM)(2016)